GentiBio is developing engineered regulatory T cells (Tregs). Tregs are the body’s natural means for keeping the immune system in balance. Tregs suppress potentially pathogenic immune activation and promote tissue repair; however, Treg activity is lost in some diseases. GentiBio is using their modular engineering platform to create optimized Tregs as powerful and tailored therapeutics for autoimmune and inflammatory diseases. GentiBio’s engineered Tregs overcome the limitations of endogenous, sorted Tregs by transforming the cells with superior phenotypes including resistance to inflammation, increased potency and scalable manufacturing. GentiBio’s most advanced product is GNTI-122, an autologous engineered Tregs product to treat type 1 diabetes.

<p>GentiBio is developing engineered regulatory T cells (Tregs). Tregs are the body’s natural means for keeping the immune system in balance. Tregs suppress potentially pathogenic immune activation and promote tissue repair; however, Treg activity is lost in some diseases. GentiBio is using their modular engineering platform to create optimized Tregs as powerful and tailored therapeutics for autoimmune and inflammatory diseases.</p>
<p>GentiBio’s engineered Tregs overcome the limitations of endogenous, sorted Tregs by transforming the cells with superior phenotypes including resistance to inflammation, increased potency and scalable manufacturing. GentiBio’s most advanced product is GNTI-122, an autologous engineered Tregs product to treat type 1 diabetes.</p>


GentiBio

A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells

GentiBio to Unveil Cutting-Edge Research at ASGCT Conference


              GentiBio - Manager, Quality Operations
            

GentiBio Announces Preclinical Data for GNTI-122, GentiBio’s Lead Candidate, an Autologous, Antigen-Specific Engineered T Regulatory Cell (EngTregs) for the Treatment of Newly Diagnosed and At-Risk Type 1 Diabetes (T1D)

GentiBio banks $157M to fuel Treg treatment for Type 1 ...

 GentiBio Nets $157M to Restore Immune Tolerance With Tregs 

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation - PR Newswire

GentiBio Nets $157 Million to Restore Immune Tolerance with Tregs - BioSpace

Treg player GentiBio turns to layoffs; Century Therapeutics CEO departs - Endpoints News

GentiBio Named A BioSpace 2023 Best Places to Work

 BMS bites at GentiBio’s next-gen regulatory T cells, betting $1.9B on 3 programs 

 Funding To North American Startups Held Steady In Q3, While Exits Rose 

 GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership 

Thomas Wickham, #Genti's CSO, presented today at the 2nd Annual Cell Therapy for Autoimmune Disease Summit in Philadelphia! #autoimmune #T1D #Tregs

 Treg player GentiBio turns to layoffs; Century Therapeutics CEO departs 

 Venture Capital Database 2020 Now Available! 

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation

 Alia Therapeutics–Nada A: board, 202305– independent Board Director main org CEO + Co-Founder at GentiBio 

 New biotech startup GentiBio lands $20M, inks licensing deals with Seattle Children’s and BRI 

 GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer 

 Immunology startup GentiBio signs $1.9B deal with Bristol Myers 

BMS bites at GentiBio's next-gen regulatory T cells, betting ...

November is Diabetes Awareness Month and GentiBio is proud to be in the fight against Type 1 Diabetes. Our innovative engineered regulatory T cell (EngTreg) therapy GNTI-122, harnesses the power of EngTregs. With GNTI-122 we aim to restore immune balance and prevent the immune system from attacking insulin-producing cells, offering a potential cure for this autoimmune disease. GNTI-122 represents a transformative shift in diabetes treatment, moving beyond symptom management toward addressing the root cause. We’re proud that our work holds the promise of significantly improving the lives of those affected by Type 1 Diabetes.  

#T1D #autoimmune #celltherapynews #celltherapy #biotech #Tregs #November #Diabetesawarenessmonth 

 BMS Bets up to $1.9 Billion on GentiBio’s Treg Treatment for IBD 

New biotech startup GentiBio lands $20M, inks licensing deals with Seattle Children's and BRI - GeekWire

GentiBio Announces Participation in Two Upcoming Investor Conferences

GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer

 GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer 

GentiBio Names Dr. Mark Bach As Chief Medical Officer - Contract Pharma

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases - BioSpace

BMS bites at GentiBio's next-gen regulatory T cells, betting $1.9B on 3 programs - Fierce Biotech

GentiBio, Forge Biologics Ink Development And Manufacturing Agreement - Contract Pharma

In December, the GentiBio #team took part in giving back to our community! The Seattle team collected food donations for Northwest Harvest; one of Washington State’s leading hunger relief agencies and advocate for food justice. The Cambridge team volunteered at the Giving Factory to help quality-check, sort, and package donations for children. Thanks to all those who helped! 
#givingback #volunteering #thankyou

www.gentibio.com

GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership - Business Wire

BioSpace NextGen Bio 2022 Winners: Where are They Now? - BioSpace

GentiBio banks $157M to fuel Treg treatment for Type 1 diabetes - Fierce Biotech

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases

 GentiBio Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer 


              GentiBio - Director/Sr. Director, Clinical Operations
            

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

As we conclude 2024, GentiBio wants to thank our people for all their hard work, collaboration and dedication! What we do would not be possible without our talented teams in Seattle and Cambridge. Each site concluded their year with a celebratory off-site gathering with games, food and laughter. As we enter our winter shutdown to recharge and spend time with our friends and families, we wish you all a happy and healthy 2025!
#thankyou #recharge #happy2025 #biotech

Happy Halloween from GentiBio to you! Our #team exercised their frightening creativity with costumes like skeletons, ghosts and chefs! Each site came together to celebrate the holiday, shared some festive treats, and enjoyed spending time together. #biotech #happyhalloween #spookyseason 

GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases - PR Newswire

GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies

GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer - PR Newswire

BMS Bets up to $1.9 Billion on GentiBio’s Treg Platform for IBD - BioSpace

WilmerHale Advises GentiBio in $157M Series A Funding - WilmerHale

GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer - BioSpace

 At an 'inflection point': GentiBio reels in $157M ahead of what CEO Adel Nada sees as a Treg boom 

Months after $1.9B deal with Bristol Myers, Boston biotech cuts workers - The Business Journals

 GentiBio Raises $20M in Seed Funding 

GentiBio - The Pharma Letter

GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes

We are pleased to introduce Mark Bach as Chief Medical Officer at GentiBio! In this role, Dr. Bach will oversee clinical development and lead clinical strategy for GentiBio’s engineered regulatory T-cell (Treg) therapeutics for the treatment of autoimmune and inflammatory conditions. Mark brings over 30 years of experience in clinical research and development from biopharmaceutical companies including Structure, Ascendis Pharma, Janssen/Johnson & Johnson, and Merck.  

Read more about it here: https://lnkd.in/gCg8QBex

GentiBio raises $157M as cell therapy for immune diseases draw investor interest - BioPharma Dive

GentiBio could earn $1.9 billion under IBD deal with BMS - The Pharma Letter

 GentiBio Announces Participation in Two Upcoming Investor Conferences 

 Gentibio raises $157M in series A, targeting type 1 diabetes with its Tregs 

 GentiBio closes Series A financing to advance its pipeline of engineered Treg therapies 

GentiBio and Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel diseases - Labiotech.eu

GentiBio launches to develop engineered regulatory T cells for autoimmune and inflammatory diseases - EurekAlert

Forge Bio wins GentiBio AAV vector contract - BioProcess Insider

The #ClinicalScience team at GentiBio is growing! We are looking for a part-time consultant to support us over the next few months. The talented individual will have training in rheumatology along with industry experience in developing cell therapies. Please reach out to Alexa (Dichio) Perdikis if you are interested or know of someone who may be interested. #biotech #hiring #rheumatology #celltherapy 

GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership

 GentiBio Raises $157M in Series A Financing 

GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases

GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs  Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of  Clinical Type 1 Diabetes (T1D)

 BioSpace Layoff Tracker 2023: Aeglea, Oncocyte, GentiBio and More Cut Staff 

 Novartis and a string of high profile backers fund next-gen Treg cell therapy startup GentiBio 

The GentiBio #team enjoyed partaking in the Breakthrough T1D Walk in Boston last week! We walked to raise money for Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization. We are honored to work for an organization that is focusing on ways to better treat and potentially cure patients with T1D.  

GentiBio

Business:

Drug notes:

About: